Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

About this update from Revelation Biosciences, Inc.

[{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced formation of an Acute Kidney Injury (AKI) Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This distinguished panel brings together internationally recognized Nephrologists and Critical Care Physicians who will guide the company's clinical strategy, monitor progress, and ensure the initiative achieves the goal of improving patient care by advancing Gemini for the treatment of AKI. Their collective insight will help inform the most pertinent study design to best address the significant unmet medical need in AKI.","length":802,"tagName":"p"},{"type":"text","content":""I am honored to serve as Principal Investigator for this important study and to collaborate closely with the team at Revelation Biosciences," said Laurence Busse, MD, MBA, FCCM. "Acute kidney injury remains a significant unmet need in critical care, and there is a clear necessity for novel therapeutic approaches that move beyond supportive care alone. What is particularly compelling about this program is its innovative mechanism, which seeks to modulate the innate immune response in a way that restores physiologic balance rather than simply suppressing inflammation. This represents a fundamentally different approach to treating complex inflammatory conditions, and I am excited to partner with Revelation to rigorously evaluate its potential to meaningfully improve outcomes for patients."","length":818,"tagName":"p"},{"type":"text","content":""I am really happy to be part of this endeavor as Gemini modulates the immune response that is fundamentally involved in the pathophysiology of organ dysfunction, including the development of AKI", said Alexander Zarbock, MD, PhD.","length":240,"tagName":"p"},{"type":"text","content":""AKI remains a major clinical challenge, particularly among hospitalized and critically ill patients," said James Rolke, Chief Executive Officer of Revelation. "We are honored to collaborate with this esteemed group of physician leaders whose expertise will be invaluable in advancing our mission to improve outcomes for patien...

More updates from Revelation Biosciences, Inc.